Parkinson Disease Survival
Open Access
- 1 April 2000
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 57 (4) , 507-512
- https://doi.org/10.1001/archneur.57.4.507
Abstract
BEFORE THE introduction of levodopa in the therapy of Parkinson disease (PD), many clinical and epidemiological reports showed that patients with PD had a shorter survival than the general population.1 Hoehn and Yahr,2 in their leading article, reported a mortality ratio 2.9 times higher than that of the general population adjusted for age, sex, and race.Keywords
This publication has 10 references indexed in Scilit:
- Epidemiology of Movement DisordersPublished by Taylor & Francis ,2019
- Mortality cancer risk in parkinsonian patients: A population-based studyNeurology, 1999
- Mortality From Parkinson DiseaseArchives of Neurology, 1997
- Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology?Journal of Neurology, Neurosurgery & Psychiatry, 1995
- Attrition and Use of Proxy Respondents and Auxiliary Information in the Sicilian Neuroepidemiologic StudyAmerican Journal of Epidemiology, 1994
- Validating screening instruments for neuroepidemiologic surveys: Experience in SicilyJournal of Clinical Epidemiology, 1992
- Multi‐center study of Parkinson mortality with early versus later dopa treatmentAnnals of Neurology, 1987
- Epidemiology of parkinsonism: Incidence, classification, and mortalityAnnals of Neurology, 1984
- Mortality among Parkinson Patients Treated with L-Dopa Combined with a Decarboxylase InhibitorEuropean Neurology, 1976
- ParkinsonismNeurology, 1967